Neuropace

NPCE · NASDAQ

$13.51+$0.74 (+5.79%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.77

NPCE analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $20.40 (+51.0% upside)

Low: $18.18
Now: $13.51
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

NPCE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Keybanc	Sep 18, 2026	Initiates	Overweight	$18.00	56%
HC Wainwright & Co.	Jul 29, 2026	Maintains	Buy	$20.00	40%
Mizuho	Jul 23, 2026	Initiates	Outperform	$22.00	56%
HC Wainwright & Co.	May 15, 2026	Maintains	Buy	$19.00 → $20.00	40%
HC Wainwright & Co.	Jan 27, 2026	Maintains	Buy	$18.00 → $19.00	40%
UBS	Dec 16, 2025	Maintains	Buy	$18.00 → $22.00	89%
JP Morgan	Dec 10, 2025	Maintains	Overweight	$18.00 → $20.00	67%
JP Morgan	Nov 5, 2025	Maintains	Overweight	$16.00 → $18.00	67%
Wells Fargo	Nov 5, 2025	Maintains	Overweight	$15.00 → $16.00	45%

The case for and against

Updated Nov 14, 2025

Bull case

NeuroPace Inc has demonstrated a significant improvement in the quality of life for patients using its RNS system, as evidenced by a meaningful increase of 3.2 points in the QOLIE-89 survey after one year of treatment. The company benefits from favorable macro trends, including a substantial increase in the number of Comprehensive Epilepsy Centers (CECs) and a 150% rise in the number of epileptologists per capita from 2012 to 2019, enhancing awareness and access to its products. Additionally, NeuroPace has reported impressive revenue growth, with a notable inflection in 2022, projecting a 75.5% increase from 2022 to 2024, which positions it favorably in the medical device sector.

Bear case

NeuroPace Inc. is facing ongoing financial challenges characterized by a consistent history of significant net losses, with no clear pathway to achieving or sustaining profitability in the near future. The company's need for additional capital may pose difficulties, leading to unfavorable funding terms that could necessitate cost-cutting measures and negatively impact its operations. Furthermore, existing financial obligations, including a restrictive term loan and uncertainty surrounding a distribution agreement, enhance the risks to its financial health and potential stock performance, compounded by challenges in market uptake and competition.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.